Brief: Belite Bio Says UK's MHRA Agrees To Conditional Marketing Authorization For Treatment Of Stargardt Disease With Tinlarebant
02/11/2025 14:03
Nov 2 (Reuters) - Belite Bio Inc BLTE.O: BELITE BIO ANNOUNCES UK’S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY AGREES TO CONDITIONAL MARKETING AUTHORIZATION APPLICATION BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT Source text: ID:nGNX3G3yF Further company coverage: BLTE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses